H. pylori Screen-and-Treat: A Practical Blueprint for Gastric Cancer Prevention
Review by Dr. Radu Alexandru Fărcaș (USA)
Study Summary
Gastric cancer remains a major global cause of cancer mortality and chronic Helicobacter pylori infection is its most important modifiable risk factor. Although eradication of H. pylori has long been recognized as a promising prevention strategy, the major knowledge gap has been how to move from evidence to population-based implementation. The IARC/WHO Working Group Report, summarized in the New England Journal of Medicine, provides guidance for implementing H. pylori screen-and-treat programs for gastric cancer prevention. The report emphasizes that such programs are most clearly justified in intermediate- and high-incidence settings, defined as age-standardized gastric cancer incidence of at least 10 cases per 100,000 person-years, but also notes that selected high-risk groups in low-incidence countries may benefit.
The Working Group recommends that implementation begin with assessment of local needs and readiness, supported by sustainable funding, governance, leadership, infrastructure, and information systems. Screening may use validated 13C-urea breath testing, stool antigen testing, or serology, with the choice guided by local prevalence, feasibility, participant preference, and cost. Eradication should be based on local antibiotic resistance data; bismuth-based quadruple therapy is favored as first-line treatment because it is less affected by clarithromycin resistance and can partly overcome metronidazole resistance. Confirmation of eradication, when performed, should use urea breath testing or stool antigen testing at least four, and ideally six, weeks after therapy. The report also stresses antibiotic stewardship, quality indicators, equity, and decision modeling to tailor programs to local context.
Commentary
This report is important because it reframes gastric cancer prevention as an implementable public health intervention rather than a purely individual clinical decision. Its major strength is its pragmatic blueprint: it does not simply recommend testing and treating H. pylori, but describes what health systems need before launching a program, like governance, funding, screening pathways, eradication protocols, quality monitoring, and equity safeguards. This is particularly relevant for countries in Central and Eastern Europe and Asia, where gastric cancer burden and H. pylori prevalence remain substantial, but organized gastric cancer prevention is still limited, and to other parts of the world where it is non-existent.
However, implementation will not be uniform worldwide. A strategy that works in a high-incidence Asian country with existing screening infrastructure may not translate directly to lower-incidence European or North American settings. Serology may be logistically attractive for large-scale screening, but it cannot reliably distinguish active from past infection without a confirmatory strategy in some settings. Antibiotic resistance is another critical limitation: without local resistance surveillance and test-of-cure capacity, eradication programs risk reduced effectiveness and unnecessary antibiotic exposure. The report appropriately highlights that effects on the microbiome and that an effective H. pylori vaccine would be the ideal long-term solution, although candidates remain preclinical.
Gastric cancer prevention is entering an implementation era. The next steps should include pilot programs, registry-based monitoring, local cost-effectiveness modeling, community engagement, and integration with existing primary care or cancer screening pathways. In Europe, ongoing initiatives such as TOGAS, GISTAR, EUROHELICAN, EUGastScreen, and Hp-EuReg will be central to defining feasible models that can be adapted across diverse healthcare systems.
Citation
Park JY, Lee Y-C, Moayyedi P, Lansdorp-Vogelaar I, Camargo MC, Tepeš B, et al. Helicobacter pylori Screen-and-Treat Programs for Gastric Cancer Prevention — IARC Working Group Report. New England Journal of Medicine. 2026;394:1131-7. DOI: 10.1056/NEJMsb2515372. (PubMed)
View past News You Can Use commentaries
